These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11586969)

  • 21. Complications of hemophilia A treatment: factor VIII inhibitors.
    Kasper CK
    Ann N Y Acad Sci; 1991; 614():97-105. PubMed ID: 1902643
    [No Abstract]   [Full Text] [Related]  

  • 22. Summary report of the First International Conference on inhibitors in haemophilia A.
    Lacroix-Desmazes S; Scott DW; Goudemand J; Van Den Berg M; Makris M; Van Velzen AS; Santagostino E; Lillicrap D; Rosendaal FR; Hilger A; Sauna ZE; Oldenburg J; Mantovani L; Mancuso ME; Kessler C; Hay CRM; Knoebl P; Di Minno G; Hoots K; Bok A; Brooker M; Buoso E; Mannucci PM; Peyvandi F
    Blood Transfus; 2017 Oct; 15(6):568-576. PubMed ID: 27893354
    [No Abstract]   [Full Text] [Related]  

  • 23. Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.
    Pascual V; Capra JD
    J Clin Invest; 1996 Mar; 97(6):1357-8. PubMed ID: 8617864
    [No Abstract]   [Full Text] [Related]  

  • 24. Factor VIII inhibitors: a continuing problem.
    Hoyer LW
    J Lab Clin Med; 1993 Mar; 121(3):385-7. PubMed ID: 8445287
    [No Abstract]   [Full Text] [Related]  

  • 25. The incidence of inhibitors in hemophilia A and the induction of immune tolerance.
    Briët E; Peters M
    Adv Exp Med Biol; 2001; 489():89-97. PubMed ID: 11554594
    [No Abstract]   [Full Text] [Related]  

  • 26. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K; Male C; Falger J; Pabinger I
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late immune tolerance induction in an adult with severe haemophilia A and high-responder inhibitor: 1-year outcome.
    Faradji A; Lavigne-Lissalde G; Grunebaum L; Desprez D; Feugeas O; Lapalud P
    Haemophilia; 2012 Sep; 18(5):e388-91. PubMed ID: 22765638
    [No Abstract]   [Full Text] [Related]  

  • 28. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Baglin T; Beacham E
    Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
    [No Abstract]   [Full Text] [Related]  

  • 30. Does peroral administration of factor VIII induce oral tolerance in patients with acquired haemophilia A?
    Lindgren A; Wadenvik H; Tarkowski A; Tengborn L
    Thromb Haemost; 2000 Apr; 83(4):632-3. PubMed ID: 10780332
    [No Abstract]   [Full Text] [Related]  

  • 31. Suggestions for the management of factor VIII inhibitors.
    Rubinger M; Rivard GE; Teitel J; Walker H;
    Haemophilia; 2000 Jul; 6 Suppl 1():52-9. PubMed ID: 10982269
    [No Abstract]   [Full Text] [Related]  

  • 32. [Therapy of immuninhibitor hemophilia A with FEIBA plasma fraction].
    István L; Bariska I; Marton E
    Orv Hetil; 1980 Dec; 121(51):3131-5. PubMed ID: 6784062
    [No Abstract]   [Full Text] [Related]  

  • 33. What can we learn from the immune response to human factor VIII in a mouse model of hemophilia A?
    Reipert BM; Schwarz HP
    Thromb Haemost; 2002 Aug; 88(2):374-5. PubMed ID: 12195723
    [No Abstract]   [Full Text] [Related]  

  • 34. Application of current knowledge to the management of bleeding events during immune tolerance induction.
    Di Paola J; Aledort L; Britton H; Carcao M; Grabowski E; Hutter J; Journeycake J; Kempton C; Leissinger C
    Haemophilia; 2006 Nov; 12(6):591-7. PubMed ID: 17083508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comments on the development of inhibitor antibodies in patients using recombinant factor VIII concentrates.
    Brettler DB
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):45-6. PubMed ID: 1908128
    [No Abstract]   [Full Text] [Related]  

  • 37. IgG subclass changes in response to replacement therapy with clotting factor VIII.
    Shakib F
    Monogr Allergy; 1986; 19():262-5. PubMed ID: 3093849
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune tolerance in hemophilia and the treatment of hemophiliacs with an inhibitor. Proceedings of a meeting. Palermo, Italy, October 1999.
    Haematologica; 2000 Oct; 85(10 Suppl):1-116. PubMed ID: 11236744
    [No Abstract]   [Full Text] [Related]  

  • 39. Hemophilia treatment. Side effects during immune tolerance induction.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Haematologica; 2000 Oct; 85(10 Suppl):75-7. PubMed ID: 11187878
    [No Abstract]   [Full Text] [Related]  

  • 40. The response to factor VIII infusion in inhibitor patients.
    Allain JP; Verroust F
    Prog Clin Biol Res; 1984; 150():99-108. PubMed ID: 6431445
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.